Autoimmune disease therapy firm Cabaletta Bio has raised $ 50 m in a series B funding round . The extra funding , which follows a $ 38 m series A , will be put to fund funding the manufacture of the uk - based company 's chimeric autoantibody receptor T cell ( CAAR - T ) therapies . This system borrows the techniques used in chimeric antigen receptor T - cell methods for cancer treatments , and instead applies them to autoimmune diseases . The CAAR - T selectively targets mucosal pemphigus vulgaris patients of DSG3 protein - expressing B cells by using the CD - 1BB costimulatory domain to boost cytokine production and a CD3-zeta signalling domain to control signalling during T - cell activation .
Autoimmune disease therapy firm Cabaletta Bio has raised $50m in a series B funding round. The extra capital, which follows a $38m series A, will be put to use funding the manufacture of the Pennsylvania-based company's chimeric autoantibody receptor T cell (CAAR-T) therapies. This system borrows the techniques used in chimeric antigen receptor T-cell methods for cancer treatments, and instead applies them to autoimmune diseases. The CAAR-T selectively rids mucosal pemphigus vulgaris patients of DSG3 protein-expressing B cells by using the 4-1BB costimulatory domain to boost cytokine production and a CD3-zeta signalling domain to control signalling during T-cell activation.